
Danish pharmaceutical company Novo Nordisk is increasing its transparency on company tax payments, and in the future it will report on more detailed information from single markets in which the firm operates, according to Danish financial media Økonomisk Ugebrev.
"Our Tax Approach was updated last year and addresses the topics which a 2020 tax policy must contain. One of the areas, which we've focused more on in this update, is transparency," Corporate Vice President, Group Tax, Camilla Wright tells this media.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.